Literature DB >> 2022975

New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose.

C K Kim1, J B Alavi, A Alavi, M Reivich.   

Abstract

Positron emission tomography (PET) using fluorine-18 (18F)-fluorodeoxyglucose (FDG) has been reported to be a powerful diagnostic and prognostic tool in patients with primary brain tumors. This study was undertaken to compare the prognostic value of: (1) visual grading of [18]FDG uptake in the tumor, (2) the absolute glucose metabolic rate of the tumor (TMRglc), (3) the ratio of glucose metabolism between the tumor and whole brain (T/WB) and (4) between the tumor and contralateral cerebellum (T/CBL). Each of these four parameters was correlated with the survival time in 20 patients with malignant cerebral gliomas. Excellent correlation was obtained with visual grading and reasonably good correlation was obtained with T/WB or T/CBL, but TMRglc alone was only a fair prognostic indicator. Thus, visual grading provides a qualitative analysis and T/WB provides a semi-quantitative analysis neither of which requires arterial blood sampling for quantification of absolute metabolic rates for glucose.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022975     DOI: 10.1007/bf00151249

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

1.  Design considerations for a positron emission transverse tomograph (PETT V) for imaging of the brain.

Authors:  M M Ter-Pogossian; N A Mullani; J T Hood; C S Higgins; D C Ficke
Journal:  J Comput Assist Tomogr       Date:  1978-11       Impact factor: 1.826

2.  PET quantitation: blessing and curse.

Authors:  G Di Chiro; R A Brooks
Journal:  J Nucl Med       Date:  1988-09       Impact factor: 10.057

3.  The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man.

Authors:  M Reivich; D Kuhl; A Wolf; J Greenberg; M Phelps; T Ido; V Casella; J Fowler; E Hoffman; A Alavi; P Som; L Sokoloff
Journal:  Circ Res       Date:  1979-01       Impact factor: 17.367

4.  Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET.

Authors:  M Kushner; M Tobin; A Alavi; J Chawluk; M Rosen; F Fazekas; J Alavi; M Reivich
Journal:  J Nucl Med       Date:  1987-11       Impact factor: 10.057

5.  Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors.

Authors:  R L DeLaPaz; N J Patronas; R A Brooks; B H Smith; P L Kornblith; H Milam; G Di Chiro
Journal:  AJNR Am J Neuroradiol       Date:  1983 May-Jun       Impact factor: 3.825

6.  Positron emission tomography in patients with glioma. A predictor of prognosis.

Authors:  J B Alavi; A Alavi; J Chawluk; M Kushner; J Powe; W Hickey; M Reivich
Journal:  Cancer       Date:  1988-09-15       Impact factor: 6.860

7.  Depressed cerebellar glucose metabolism in supratentorial tumors.

Authors:  N J Patronas; G Di Chiro; B H Smith; R De La Paz; R A Brooks; H L Milam; P L Kornblith; D Bairamian; L Mansi
Journal:  Brain Res       Date:  1984-01-16       Impact factor: 3.252

8.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

9.  Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain.

Authors:  N J Patronas; G Di Chiro; R A Brooks; R L DeLaPaz; P L Kornblith; B H Smith; H V Rizzoli; R M Kessler; R G Manning; M Channing; A P Wolf; C M O'Connor
Journal:  Radiology       Date:  1982-09       Impact factor: 11.105

10.  Metabolic and hemodynamic evaluation of gliomas using positron emission tomography.

Authors:  J L Tyler; M Diksic; J G Villemure; A C Evans; E Meyer; Y L Yamamoto; W Feindel
Journal:  J Nucl Med       Date:  1987-07       Impact factor: 10.057

View more
  18 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

2.  Prediction of pathology and survival by FDG PET in gliomas.

Authors:  M V Padma; S Said; M Jacobs; D R Hwang; K Dunigan; M Satter; B Christian; J Ruppert; T Bernstein; G Kraus; J C Mantil
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

Review 3.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

4.  [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms.

Authors:  D S Rosenberg; G Demarquay; A Jouvet; D Le Bars; N Streichenberger; M Sindou; N Kopp; F Mauguière; P Ryvlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

5.  Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.

Authors:  Heejin Kim; Kyung Jin Na; Jae Hyuk Choi; Byeong-Cheol Ahn; Dongbin Ahn; Jin Ho Sohn
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

Review 6.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

7.  FDG-PET as a prognostic factor in high-grade astrocytoma.

Authors:  O De Witte; F Lefranc; M Levivier; I Salmon; J Brotchi; S Goldman
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

8.  MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.

Authors:  F W Floeth; A Aulich; K J Langen; K J Burger; W J Bock; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

Review 9.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Authors:  Ashish H Shah; Brian Snelling; Amade Bregy; Payal R Patel; Danoushka Tememe; Rita Bhatia; Evelyn Sklar; Ricardo J Komotar
Journal:  J Neurooncol       Date:  2013-01-24       Impact factor: 4.130

10.  Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions.

Authors:  T Kuwert; C Morgenroth; B Woesler; P Matheja; S Palkovic; B Vollet; S Samnick; U Maasjosthusmann; H Lerch; F J Gildehaus; H Wassmann; O Schober
Journal:  Eur J Nucl Med       Date:  1996-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.